ResMed (NYSE: RMD ) is expected to report Q4 earnings on Aug. 2. Here's what Wall Street wants to see.
The 10-second takeaway
Comparing the upcoming quarter with the prior-year quarter, average analyst estimates predict ResMed's revenues will expand 8.6% and EPS will improve 25.6%.
The average estimate for revenue is $371.3 million. On the bottom line, the average EPS estimate is $0.49.
Last quarter, ResMed booked revenue of $349.1 million. GAAP reported sales were 11% higher than the prior-year quarter's $313.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.46. GAAP EPS of $0.44 for Q3 were 29% higher than the prior-year quarter's $0.34 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 60.3%, 200 basis points better than the prior-year quarter. Operating margin was 22.2%, 180 basis points better than the prior-year quarter. Net margin was 18.5%, 150 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $1.36 billion. The average EPS estimate is $1.72.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 171 members out of 185 rating the stock outperform, and 14 members rating it underperform. Among 50 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 48 give ResMed a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on ResMed is outperform, with an average price target of $30.87.
The healthcare investing landscape is littered with also-rans and a few major winners. Is ResMed the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Get instant access to this free report.
- Add ResMed to My Watchlist.